Associated Papers
Exome Sequencing Identifies Variants in MLH1 and ERBB2 as Potential Cancer-Predisposing Factors in Familial Early-Onset Colorectal Cancer.
Bagheri B et al.
The Kaohsiung Journal of Medical Sciences, 2026
The GigaAssay: A combined high throughput and highly accurate platform for variant classification.
Giacoletto CJ et al.
New Biotechnology, 2025
High-throughput characterization of 5886 HER2 variants identifies 112 new in cellulo gain-of-function mutations.
Giacoletto CJ et al.
Genomics, 2025
Genomic landscape of endometrial polyps.
Reinikka S et al.
Genome Medicine, 2025
Molecular characterization of colorectal cancer (CRC) using next generation sequencing (NGS) in bridging the gap between research and clinical practice: from biomarker discovery to clinical implementation.
Afolabi HA et al.
Discover Oncology, 2025
New Gain-of-Function Mutations Prioritize Mechanisms of HER2 Activation.
Giacoletto CJ et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
Trastuzumab deruxtecan for the treatment of metastatic non-small cell lung cancer harboring HER2 non-exon 19/20 mutations: four case reports.
Meng Y et al.
Frontiers in Immunology, 2025
Somatic mutations in 3929 HPV positive cervical cells associated with infection outcome and HPV type.
Pinheiro M et al.
Nature Communications, 2024
Targeted next-generation sequencing of 491 lung cancers in clinical practice: Implications for future detection strategy and targeted therapy.
Liu XD et al.
Heliyon, 2024
CHB patients with rtA181T-mutated HBV infection are associated with higher risk hepatocellular carcinoma due to increases in mutation rates of tumour suppressor genes.
Ning Q et al.
Journal of Viral Hepatitis, 2023
Clinical characteristics and treatment outcomes of HER2 mutation and HER2 fusion in 22 patients with advanced breast cancer.
Mu Y et al.
Thoracic Cancer, 2023
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.
Jhaveri K et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2023
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.
Harding JJ et al.
Nature Communications, 2023
ERBB family fusions are recurrent and actionable oncogenic targets across cancer types.
Schubert L et al.
Frontiers in Oncology, 2023
Diverse Molecular Mechanisms Underlying Pathogenic Protein Mutations: Beyond the Loss-of-Function Paradigm.
Backwell L et al.
Annual Review of Genomics and Human Genetics, 2022
Poziotinib Inhibits HER2-Mutant-Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer.
Kalra R et al.
Cancer Research, 2022
Molecular Landscape of ERBB2 Alterations in 14,956 Solid Tumors.
Wang H et al.
Pathology Oncology Research : Por, 2022
Mutation profile and immunoscore signature in thymic carcinomas: An exploratory study and review of the literature.
Asselta R et al.
Thoracic Cancer, 2021
Genetic aberrations in Chinese pancreatic cancer patients and their association with anatomic location and disease outcomes.
Lu J et al.
Cancer Medicine, 2021
Efficacy and Resistance of Afatinib in Chinese Non-Small Cell Lung Cancer Patients With HER2 Alterations: A Multicenter Retrospective Study.
Song Z et al.
Frontiers in Oncology, 2021
A step towards personalizing next line therapy for resected pancreatic and related cancer patients: A single institution's experience.
Lowder CY et al.
Surgical Oncology, 2020
Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers.
Subramanian J et al.
The Oncologist, 2019
Development and validation of a targeted gene sequencing panel for application to disparate cancers.
McCabe MJ et al.
Scientific Reports, 2019
Finding driver mutations in cancer: Elucidating the role of background mutational processes.
Brown AL et al.
Plos Computational Biology, 2019
Targeted mutation detection in breast cancer using MammaSeq™.
Smith NG et al.
Breast Cancer Research : Bcr, 2019
Validation of the Oncomine™ focus panel for next-generation sequencing of clinical tumour samples.
Williams HL et al.
Virchows Archiv : an International Journal of Pathology, 2018
Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma.
Kim YS et al.
Bmc Urology, 2018
Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.
Ross JS et al.
Cancer, 2018
Molecular Characterization of Urothelial Carcinoma of the Bladder and Upper Urinary Tract.
Lee JY et al.
Translational Oncology, 2018
Frequency, impact and a preclinical study of novel ERBB gene family mutations in HER2-positive breast cancer.
Elster N et al.
Therapeutic Advances in Medical Oncology, 2018
Integrated Exploitation of the Structural Diversity Space of Chemotherapy Drugs to Selectively Inhibit HER2 T798M Mutant in Lung Cancer.
Wang YW et al.
Chemistry & Biodiversity, 2017
Activating HER2 mutations as emerging targets in multiple solid cancers.
Connell CM et al.
Esmo Open, 2017
Clinical significance of frequent somatic mutations detected by high-throughput targeted sequencing in archived colorectal cancer samples.
Dallol A et al.
Journal of Translational Medicine, 2016
Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer.
Lee JY et al.
Oncotarget, 2015
Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor.
Hu Z et al.
Oncotarget, 2015
Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay.
Park K et al.
Oncotarget, 2015
Phosphorylation of mutationally introduced tyrosine in the activation loop of HER2 confers gain-of-function activity.
Hu Z et al.
Plos One, 2015